Is topiramate contraindicated in a patient using a Nexplanon (etonogestrel) implant?

Topiramate is NOT absolutely contraindicated with Nexplanon, but significant caution is warranted due to documented drug interactions that can reduce contraceptive efficacy

Key Drug Interaction Evidence

Topiramate reduces etonogestrel (Nexplanon) serum concentrations, potentially compromising contraceptive effectiveness. A prospective pharmacokinetic study demonstrated that topiramate at antiepileptic doses (400 mg/day) caused serum etonogestrel levels to fall below the ovulatory suppression threshold (90 pg/mL) in approximately 31% of implant users 1. The study showed progressive decreases in etonogestrel concentrations: median levels dropped from 142 pg/mL at baseline to 105 pg/mL at 6 weeks of topiramate 400 mg/day, with confidence intervals indicating potential decreases up to 67% 1.

Dose-Dependent Considerations

Lower Doses (≤200 mg/day)

• For migraine prophylaxis doses (100 mg/day): Real-world evidence from 63,649 episodes of concomitant oral contraceptive and topiramate use showed NO increased risk of unintended pregnancy at low doses (≤200 mg/day), with contraception failure rates of 1.3 per 100 person-years, identical to comparator groups 2
• However, this evidence applies to oral contraceptives, not specifically to Nexplanon

Higher Doses (≥400 mg/day)

• For antiepileptic doses: The pharmacokinetic interaction becomes clinically significant 1
• Network meta-analysis data suggests topiramate 200 mg/day has comparable effects to 50 mg/day on hormonal contraceptive exposure 3

Clinical Management Algorithm

If topiramate is being prescribed to a Nexplanon user:

1. Assess the topiramate dose:

   • ≤100 mg/day (migraine dose): Nexplanon can likely be continued, but counsel patient about theoretical risk
   • >100-200 mg/day: Consider additional barrier contraception or alternative contraceptive method
   • ≥400 mg/day (antiepileptic dose): Strongly recommend additional barrier contraception or switching to a non-hormonal contraceptive method (copper IUD)

2. Counsel patients explicitly:

   • Topiramate can reduce contraceptive implant effectiveness, particularly at higher doses 4, 5
   • Women must use reliable backup contraception (condoms) consistently when taking higher-dose topiramate
   • Critical teratogenicity concern: Topiramate itself causes birth defects (oral clefts), making contraceptive failure particularly dangerous 4, 6, 7

3. Consider alternative medications:

   • For migraine: propranolol, amitriptyline (no contraceptive interaction) 8
   • For epilepsy: levetiracetam, lamotrigine (minimal interaction) 9

Guideline Recommendations

Multiple obesity management guidelines explicitly warn that topiramate reduces the efficacy of hormonal contraceptives 4, 5. The 2022 AGA guideline states: "Women of childbearing potential should be counseled on the risks of teratogenicity and consistent use of reliable contraception while using phentermine-topiramate ER" 4. The 2018 IIH consensus guidelines specifically note: "Where topiramate is prescribed, women must be informed that it can reduce the efficacy of the contraceptive pill/oral contraceptives and other hormonal contraceptives" 5.

The 2010 U.S. Medical Eligibility Criteria for Contraceptive Use classifies certain anticonvulsants (including topiramate) as Category 3 for progestin-only pills and Category 2 for implants, meaning "theoretical or proven risks usually outweigh advantages" for pills, but "advantages generally outweigh risks" for implants 9. However, this predates the 2022 pharmacokinetic data showing significant etonogestrel reduction 1.

Critical Pitfalls to Avoid

• Do not assume low-dose topiramate is completely safe - even 50-200 mg/day shows enzyme-inducing effects 3
• Do not forget the dual risk: Both contraceptive failure AND topiramate teratogenicity create compounded danger
• Do not rely solely on Nexplanon in patients requiring chronic topiramate ≥200 mg/day without backup contraception
• Monitor for breakthrough bleeding as a potential sign of reduced contraceptive hormone levels

Bottom line: While not an absolute contraindication, the combination requires enhanced counseling, consideration of backup contraception (especially at doses >100 mg/day), and awareness that topiramate's teratogenic potential makes contraceptive failure particularly hazardous. 4, 5, 1